Shots:

• EMA has accepted to review the MAA for SB11- a proposed biosimilar referencing Lucentis (ranibizumab). If approved- SB11 will join a growing number of biosimilars developed by Samsung Bioepis and commercialized by Biogen
• In Nov 2019- Samsung Bioepis announced that it entered into a new commercialization agreement with Biogen for two ophthalmology biosimilar candidates: SB11 (ranibizumab) and SB15 (aflibercept) in the US- Canada- Europe- Japan- and Australia
• Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders- which are a leading cause of blindness

 ­ Ref: BIOGEN | Image:Biogen